Search peptides, terms, sources/
Research source · 2025

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
3,417 adults with overweight/obesity and 1 or more comorbidity, without type 2 diabetes
Sample size
3417
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Sponsor-funded (Novo Nordisk); studies the fixed-dose combination as the primary comparison, not cagrilintide as a standalone agent.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.